Pravin Shende

@nmims.edu

Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management
SVKMs NMIMS



        

https://researchid.co/shendepravin94
195

Scopus Publications

Scopus Publications





  • Engineering of Layered Nanocarriers of Quercetin for the Treatment of Diabetes Using Box-Behnken Design
    Priyank Shah and Pravin Shende
    Wiley
    AbstractLayered nanocarriers are polymeric systems integrated with layers of glucose‐responsive polymers and polyethylene glycol monomethyl ether 2000 PEG2000 to enhance the targeting effect and release kinetics. The prime purpose of this research study is to demonstrate a controlled release of Quercetin from formulation of quercetin (Qu)‐based layered nanocarriers (LNCs) with higher stability and anti‐diabetic activity. The QuLNCs are synthesized using the nanoprecipitation method and optimized by Box‐Behnken design of the Design of Experiment (DoE) method. The Quercetin Nanoparticles (QuNPs) are prepared using Polyvinyl alcohol (PVA) and Poly (D,L‐ lactic‐co‐glycolic acid) (PLGA) polymers where the two layers of Phenylboronic acid (PBA) are conjugated using 3‐amino propyl‐triethoxysilane (APTES) as a functionalizing agent followed by PEGylation of the entire system using PEG2000. The optimized QuLNCs are characterized by various parameters like Particle size (PS), Zeta potential (ZP), % Entrapment efficiency (%EE), Attenuated total reflectance‐ Fourier Transform Infrared Spectroscopy (ATR‐FTIR), Differential scanning Calorimetry (DSC), Transmission electron microscopy (TEM), in vitro as well as in vivo studies. The QuLNCs showed a % entrapment efficiency of 82.846 ± 0.957% and release of 85.04 ± 3.21% of Qu for 24 h from the layered nanocarriers. The in vivo studies of QuLNCs exhibited a significant controlled release of quercetin for modulating blood glucose levels. Hence, these results proved QuLNCs system acts as a favorable approach for the treatment of type 1 diabetes to offer a longer duration of action.

  • Current scenario and potential of music therapy in the management of diseases
    Sayali Bhandarkar, Bhagyashree V. Salvi, and Pravin Shende
    Elsevier BV


  • Blind Spots in Development of Nanomedicines
    Bhagyashree V. Salvi, Maithali Kantak, Kalyani Kharangate, Francesco Trotta, Timothy Maher, and Pravin Shende
    SAGE Publications
    The field of nanomedicine demonstrates immense advantages and noteworthy expansion compared to conventional drug delivery systems like tablet, capsules, etc. Despite the innumerable advantages, it holds certain shortcomings in the form of blind spots that need to be assessed before the successful clinical translation. This perspective highlights the foremost blind spots in nanomedicine and emphasizes the challenges faced before the entry into the market, including the need for provision of safety and efficacy data by the regulatory agencies like FDA. The significant revolution of nanomedicine in the human life, particularly in patient well-being, necessitates to identify the blind spots and overcome them for effective management and treatment of ailments.

  • Potentiation of Brain Bioavailability Using Thermoreversible Cubosomal Formulation
    Harshvardhan Jain, Bala Prabhakar, and Pravin K. Shende
    American Chemical Society (ACS)
    The aim of the present study was to develop and evaluate intranasal formulations of the thermoreversible fluoxetine cubosomal in situ gel. This gel was intended for permeation and bioavailability enhancement to target the brain effectively by bypassing the blood-brain barrier (BBB). Fluoxetine-loaded cubosomes were prepared by the homogenization method followed by the cold method approach to develop in situ gel. Fluoxetine-loaded cubosomes displayed a higher encapsulation efficiency (82.60 ± 1.25%) than fluoxetine. This might be due to the solubilizing activity of the polymer to cause partitioning of the lipophilic drug into the aqueous phase during the change from the cubic gel phase to cubosomes. In vitro analysis of fluoxetine-loaded cubosomal in situ gel showed a sustained release profile (93.22 ± 2.47%) due to limited diffusion of fluoxetine. The formation of strong affinity bonds of the drug with GMO (drug transporter) decreased the drug release in comparison to that with fluoxetine-loaded cubosomes (90.68 ± 1.74%). The ex vivo drug release profile revealed the drug release of 96.31 ± 2.88% by the end of 24 h. This is attributed to the higher capability of the intranasal cubosomal in situ gel to prolong the retention and enable better permeation through the nasal mucosa. In male Wistar rats, in vivo biodistribution studies for cubosomal in situ gel administered via the intranasal route at a dose of 3.5 mg/kg demonstrated an increase in pharmacokinetic parameters like the AUC (406 ± 75.35 μg/mL), Cmax (368.07 ± 0.23 μg/mL), Tmax (4 h), and t1/2 (14.06 h). The mucoadhesive nature of the in situ gel led to an increase in the residence time of the gel in the nasal mucosa. The biodistribution study of intranasal in situ cubosomal gel improved the bioavailability 2.21-fold in comparison to that with the cubosomal dispersion but 2.83-fold in comparison to that with the drug solution. Therefore, fluoxetine-loaded cubosomal in situ gel proved as a promising carrier for effective transportation of fluoxetine via the intranasal route with significant brain bioavailability.

  • BSA nanoclusters-based sensor for detection of dopamine in schizophrenia from biofluids
    Bhakti Khanolkar and Pravin Shende
    Informa UK Limited
    OBJECTIVE Development of non-toxic and stable fluorescent emission B-Cu nanoclusters (NCs) for the specific detection of dopamine at low concentrations in cerebrospinal fluid (CSF). SIGNIFICANCE Fluorescent gold and copper nanoclusters conjugated with proteins, such as Bovine Serum Albumin (BSA), offer photostability and healthcare potential. This study focused on fabricating B-Cu NCs that exhibited superior characteristics, for sensitive dopamine detection. METHODS The study employed various instrumental techniques including Attenuated Total Reflectance Fourier-Transform Infrared Spectroscopy (ATR-FTIR), Scanning Electron Microscopy (SEM), Spectrofluorometry, and Transmission Electron Microscopy (TEM) to characterise the formulated B-Cu NCs. The NCs were synthesized, resulting in particle size ∼300 nm. The highest observed fluorescence was recorded at 24542.81 Relative Fluorescence Units (RFU). RESULTS The introduction of dopamine at concentrations of 0.1, 0.2, 0.3, and 0.4 ng/ml led to decreased fluorescence in both B-Au and B-Cu NCs due to an electron transport system. This reduction in fluorescence allowed dopamine concentration analysis in phosphate buffer and biological fluids such as blood plasma and CSF. B-Cu NCs showed potential as a biosensing system for Point-Of-Care (POC) applications, specifically for diagnosing schizophrenia. CONCLUSIONS The study successfully synthesized stable and non-toxic B-Cu nanoclusters with enhanced fluorescent emission properties. These nanoclusters exhibited the capacity to detect dopamine at low concentrations in CSF. The study's findings hold promise for future applications, particularly in the development of a B-Cu NCs-based biosensing system for convenient POC detection of schizophrenia by both patients and clinicians. The potential impact of this technology on healthcare and biomedical fields is substantial.

  • Strategic aspect for improving the sensitivity of nanoparticles in biomedical sciences
    Kanchi Acharya, Bhagyashree V. Salvi, and Pravin Shende
    Informa UK Limited

  • Manipulation of biophysicochemical behavior of transporters using nanodimensional coating
    Jheel Dholakia, Bala Prabhakar, Jay Bajaj, and Pravin Shende
    Informa UK Limited

  • Anti-CD64 Antibody-Conjugated PLGA Nanoparticles Containing Methotrexate and Gold for Theranostics Application in Rheumatoid Arthritis
    Sahil Gandhi and Pravin Shende
    Springer Science and Business Media LLC
    Rheumatoid arthritis, an autoimmune disorder, exerts a considerable effect on quality of life. The inflammatory mechanism involved in rheumatoid arthritis is not clearly known, and therefore the need to develop effective medicines as well as new methods for early detection is a challenge. In this study, we developed PLGA nanoparticles containing gold and methotrexate in core and anti-CD64 antibody conjugated to nanoparticle surface via coupling process. The nanoparticles were examined for their surface morphology using SEM and TEM. The mean particle size, zeta potential, and PDI values of nanoparticles were 413.6 ± 2.89 nm, −10.12 ± 2.12 mV, and 0.23 ± 0.04, respectively, indicating good stability and particle homogeneity . In vitro drug release revealed a controlled release pattern with 93.44 ± 1.60% up to 72 h of release in the presence of pH 5.8, indicating the influence of pH and NIR on drug release. In vivo results on adjuvant-induced arthritis on Wistar rats indicated that animals receiving antibody-conjugated nanoparticles showed improvement in clinical indices and arthritic score as compared to non-conjugated nanoparticles and free drugs. This innovative drug delivery system will be an excellent strategy to maximize therapeutic effectiveness by limiting dosage-related side effects. Graphical Abstract

  • Interdigitation of lipids for vesosomal formulation of ergotamine tartrate with caffeine: a futuristic trend of intranasal route
    Preeti Dali and Pravin Shende
    Informa UK Limited
    Objective: This research work aimed to form vesosomes using combination of two drugs ergotamine and caffeine for synergistic activity when given intranasally resulting in faster absorption, steric stability and controlled release.Significance: The multicompartment vesicles viz., vesosomes of ergotamine tartrate proved to increase absorption of drugs post-intranasal administration, bypassing the blood-brain barrier via the olfactory pathwayMethods: The phospholipids like soya lecithin, cholesterol and dipalmitoyl phosphatidylcholine were used to form a multicompartment structure called vesosomes using ethanol-induced interdigitation of lipids as the preparation method.Results: The formulation showed low particle size of 315.48 ± 14.27 nm with zeta potential of -21.78 ± 4.72 mV, higher % EE of 91.13 ± 1.29% and controlled release kinetics, when assessed for in-vitro and ex-vivo studies as 97.64 ± 5.13% and 82.25 ± 3.27% release, respectively. Vesosomes displayed several advantages over liposomes like improved stability against phospholipase-induced enzymatic degradation and higher brain uptake 3.41-fold increase of ergotamine via the olfactory pathway.Conclusion: The stable vesosomes prepared using interdigitation of saturated phospholipids proved to be a viable option for ergotamine when administered intranasally for better absorption and bioavailability coupled with ease of administration gaining wider patient acceptance.

  • Zinc-Phthalocyanine Loaded PLGA-PVA-Chitosan Nanosystem for the Enhancement of Antidiabetic Activity
    Sharayu Govardhane and Pravin Shende
    American Chemical Society (ACS)
    Zinc, one of the most common nutraceutical agents, proved to be effective for diabetes as it regulates the blood glucose level by inhibiting glucagon secretion. However, the hepatotoxicity of zinc creates necrosis, hepatic glycogen depletion, and apoptosis of hepatocytes at the concentration of 10 μg/kg. Phthalocyanine, a blue-colored compound, is an aromatic macrocyclic compound with good antioxidant ability owing to its heterocyclic nitrogen conjugation. The conjugation of zinc with phthalocyanine aimed to reduce the toxicity associated with zinc and enhance the antidiabetic activity at a lower dose. Hence, the present research work possessed the insights of the synthetic aspect of zinc with phthalocyanine along with its entrapment in the poly(lactic-co-glycolic acid) (PLGA)-chitosan nanosystem via oral administration in the treatment of diabetes. A nanoprecipitation technique was implemented for the synthesis of PLGA chitosan nanoparticles, and formulation was further optimized using a central composite design. Twenty trials provided by the software selected optimum concentrations of PLGA, poly(vinyl alcohol) (PVA), and chitosan in consideration with particle size up to 335.6 nm, zeta potential 27.87 mV, and entrapment efficiency of 75.67 ± 8.13%. Addition of chitosan to the nanocarrier system for controlling the release of the drug for 3 days was accompanied by the improvement in the glucose level within 28 days. The delivery of the nanoparticles showed enhancement in the cholesterol, triglyceride, alkaline phosphatase (ALP), urine parameters, and pro-inflammatory cytokines. The application of DoE (design of experiments) for the optimization of the nanoparticles established a controlled release formulation for diabetes, which displayed safety and effectiveness in streptozotocin (STZ)-induced diabetic rats.


  • Phthalocyanine-based glucose-responsive nanocochleates for dynamic prevention of β-cell damage in diabetes
    Sharayu Govardhane and Pravin Shende
    Informa UK Limited
    Phthalocyanine is a blue-colored macrocyclic compound with excellent anti-oxidant and lipid-peroxidation abilities due to its intermolecular π-π stacking structure. Antioxidants inhibit intracellular reactive oxygen species formation and decrease oxidation defense ability of the enzymes in diabetes management. The present study aimed to fabricate concanavalin A conjugated phthalocyanine-loaded cochleates (Formulation PhConA) as a glucose-sensitive lipidic system and estimate its efficacy in streptozotocin-induced male Sprague Dawley diabetic rats for 28 days. Thin-film hydration and trapping methods were used in the preparation of liposomes and cochleates, respectively, whereas the surface was modified for concanavalin A conjugation using EDAC: NHS (1:1). Formulation PhConA with rod-shaped structures showed particle size of 415.7 ± 0.46 nm, PdI value of 0.435 ± 0.09, encapsulation efficiency of 85.64 ± 0.34%, and 84.55 ± 0.29% release of phthalocyanine for 56 h. The circular dichroism study displayed a slight deviation after the conjugation effect of concanavalin A to cochleates. The in-vivo studies of the formulation PhConA improved the blood glucose levels along with defensive effect on the liver to overcome the hyperlipidemic effect. The rigid structure of cochleates prolongs the drug elimination from systemic circulation and extends its effect for a longer duration by decreasing the blood glucose level. Thus, the glucose-sensitive formulation PhConA showed significant improvement in diabetic rats within the period of 28 days by improving the oxidative defense and protecting the pancreatic β-cells.

  • Evasion of opsonization of macromolecules using novel surface-modification and biological-camouflage-mediated techniques for next-generation drug delivery
    Parth Mehta and Pravin Shende
    Wiley
    AbstractOpsonization plays a pivotal role in hindering controlled drug release from nanoformulations due to macrophage‐mediated nanoparticle destruction. While first and second‐generation delivery systems, such as lipoplexes (50–150 nm) and quantum dots, hold immense potential in revolutionizing disease treatment through spatiotemporal controlled drug delivery, their therapeutic efficacy is restricted by the selective labeling of nanoparticles for uptake by reticuloendothelial system and mononuclear phagocyte system via various molecular forces, such as electrostatic, hydrophobic, and van der Waals bonds. This review article presents novel insights into surface‐modification techniques utilizing macromolecule‐mediated approaches, including PEGylation, di‐block copolymerization, and multi‐block polymerization. These techniques induce stealth properties by generating steric forces to repel micromolecular‐opsonins, such as fibrinogen, thereby mitigating opsonization effects. Moreover, advanced biological methods, like cellular hitchhiking and dysopsonic protein adsorption, are highlighted for their potential to induce biological camouflage by adsorbing onto the nanoparticulate surface, leading to immune escape. These significant findings pave the way for the development of long‐circulating next‐generation nanoplatforms capable of delivering superior therapy to patients. Future integration of artificial intelligence‐based algorithms, integrated with nanoparticle properties such as shape, size, and surface chemistry, can aid in elucidating nanoparticulate‐surface morphology and predicting interactions with the immune system, providing valuable insights into the probable path of opsonization.


  • Amalgamation of Artificial Intelligence with Nanoscience for Biomedical Applications
    Kaustubh Kasture and Pravin Shende
    Springer Science and Business Media LLC



  • Advances of nanoworms in diagnosis, treatment, and theranostics
    Kadambari Borse and Pravin Shende
    Royal Society of Chemistry (RSC)
    Nanoworms demonstrate remarkable potential as versatile nanocarriers, delivering therapeutic agents precisely to target sites, enabling accurate disease diagnosis, and advancing personalized medicine.

  • 3D-to-4D Structures: an Exploration in Biomedical Applications
    Kadambari Borse and Pravin Shende
    Springer Science and Business Media LLC
    3D printing is a cutting-edge technique for manufacturing pharmaceutical drugs (Spritam), polypills (guaifenesin), nanosuspension (folic acid), and hydrogels (ibuprofen) with limitations like the choice of materials, restricted size of manufacturing, and design errors at lower and higher dimensions. In contrast, 4D printing represents an advancement on 3D printing, incorporating active materials like shape memory polymers and liquid crystal elastomers enabling printed objects to change shape in response to stimuli. 4D printing offers numerous benefits, including greater printing capacity, higher manufacturing efficiency, improved quality, lower production costs, reduced carbon footprint, and the ability to produce a wider range of products with greater potential. Recent examples of 4D printing advancements in the clinical setting include the development of artificial intravesicular implants for bladder disorders, 4D-printed hearts for transplant, splints for tracheobronchomalacia, microneedles for tissue wound healing, hydrogel capsules for ulcers, and theragrippers for anticancer drug delivery. This review highlights the advantages of 4D printing over 3D printing, recent applications in manufacturing smart pharmaceutical drug delivery systems with localized action, lower incidence of drug administration, and better patient compliance. It is recommended to conduct substantial research to further investigate the development and applicability of 4D printing in the future.